Terazosin

Jump to navigation Jump to search
Terazosin
Terazosin®, Hytrin® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings
Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Terazosin
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

For patient information about Terazosin, click here.

Synonyms / Brand Names: Terazosin HCl, Terazosin hydrochloride, Terazosina, Terazosine, Terazosinum, Trazosin HCl, Abbott 45975, Blavin, Flumarc, Fosfomic, Heitrin, Hytracin, Hytrin, Hytrinex, Itrin, Urodie, Vasocard, Vasomet, Vicard

Overview

Terazosin (marketed as Hytrin or Zayasel) is a selective alpha 1 antagonist used for treatment of symptoms of an enlarged prostate (BPH). It also acts to lower the blood pressure, and is therefore a drug of choice for men with hypertension and prostate enlargement.

It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls.

Most common side effects include dizziness, drowsiness, headache, constipation, loss of appetite, fatigue, nasal congestion or dry eyes, but they generally go away after only a few days of use. Therapy should always be started with a low dose to avoid first dose phenomenon.[1] Sexual side effects are rare, but may include priapism or erectile dysfunction.

Category

Alpha adrenergic blockers.

FDA Package Insert

TERAZOSIN®

Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages

Mechanism of Action

References